Inventor · disambiguated record
Barbara Brannetti
Also filed as: BRANNETTI BARBARA
21 granted patents·9 pending applications·215 citations·filing 2008–2024
95Inventor score
Top patents by PatentIndex Score
30 records- 0198US10981990B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Apr 20, 2021·11 cites·30 claims
- 0298US9605070B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·67 cites·85 claims
- 0396US10525083B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2017·Granted Jan 7, 2020·15 cites·33 claims
- 0496US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0595US11155620B2Method of detecting TIM-3 using antibody molecules to TIM-3NOVARTIS AG·Filed 2019·Granted Oct 26, 2021·6 cites·20 claims
- 0694US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 0794US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 0893US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 0993US10472419B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 12, 2019·12 cites·57 claims
- 1093US9884913B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Feb 6, 2018·12 cites·30 claims
- 1192US9376489B2IL-18 binding moleculesBARDROFF MICHAEL OTTO·Filed 2013·Granted Jun 28, 2016·14 cites·25 claims
- 1290US9051365B2Antibodies that bind factor PNOVARTIS AG·Filed 2012·Granted Jun 9, 2015·18 cites·11 claims
- 1389US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 1487US2025034240A1Il-18 binding moleculesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1583US11111293B2IL-18 binding moleculesNOVARTIS AG·Filed 2018·Granted Sep 7, 2021·1 cites·15 claims
- 1682US2025213684A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2024·Application pending·0 cites
- 1780US12037378B2Variant CD58 domains and uses thereofNOVARTIS AG·Filed 2020·Granted Jul 16, 2024·1 cites·16 claims
- 1880US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1979USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 2078US2022185883A1Method of detecting tim-3 using antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2176US10081677B2IL-18 binding moleculesBARDROFF MICHAEL OTTO·Filed 2016·Granted Sep 25, 2018·1 cites·6 claims
- 2276US2022098296A1Il-18 binding moleculesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2374US9988440B2Compositions comprising antibodies targeting factor PNOVARTIS AG·Filed 2014·Granted Jun 5, 2018·2 cites·33 claims
- 2472US2024368266A1Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereofUNIV ZUERICH·Filed 2023·Application pending·0 cites
- 2570US2022133889A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2665US11851484B2Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereofUNIV ZUERICH·Filed 2020·Granted Dec 26, 2023·0 cites·21 claims
- 2764US10865237B2Nucleic acids encoding anti-Factor P antibodiesNOVARTIS AG·Filed 2018·Granted Dec 15, 2020·0 cites·11 claims
- 2856US2018207273A1Combination therapies comprising antibody molecules to tim-3DRANOFF GLENN·Filed 2016·Application pending·0 cites
- 2954US10889643B2Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereofNOVARTIS AG·Filed 2017·Granted Jan 12, 2021·0 cites·17 claims
- 3049US2010322930A1Fibronectin-based binding molecules and their useKOLBINGER FRANK·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Barbara Brannetti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →